GENOR BIOPHARMA DL-00002 (67N0) — Working Capital to Net Assets Ratio
GENOR BIOPHARMA DL-00002 (67N0) has a Working Capital to Net Assets ratio of 75.2% as of June 2025. Working capital of €826.55 Million (current assets of €1.04 Billion minus current liabilities of €210.55 Million) is measured against net assets of €1.10 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
GENOR BIOPHARMA DL-00002 Working Capital to Net Assets (2021–2024)
This chart shows how GENOR BIOPHARMA DL-00002's Working Capital to Net Assets ratio has evolved across 4 annual periods from 2021 to 2024. As of June 2025, the ratio stands at 75.2%, reflecting working capital of €826.55 Million against net assets of €1.10 Billion EUR. For the complete balance sheet picture, see balance sheet size of GENOR BIOPHARMA DL-00002.
Annual Working Capital to Net Assets for GENOR BIOPHARMA DL-00002 (2021–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for GENOR BIOPHARMA DL-00002 from 2021 to 2024, covering 4 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Read 67N0 current and long-term liabilities for a breakdown of total debt and financial obligations.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 82.1% | €945.21 Million | €1.15 Billion | €1.07 Billion | €122.09 Million | ▼ -2.9 pp |
| 2023 | 85.0% | €1.01 Billion | €1.19 Billion | €1.24 Billion | €229.53 Million | ▲ +4.1 pp |
| 2022 | 80.9% | €1.46 Billion | €1.81 Billion | €1.72 Billion | €260.39 Million | ▼ -2.3 pp |
| 2021 | 83.2% | €2.07 Billion | €2.49 Billion | €2.39 Billion | €313.19 Million | — |